Tetrasubstituted imidazole inhibitors of cytokine release: Probing substituents in the N-1 position

被引:181
作者
Laufer, SA [1 ]
Zimmermann, W [1 ]
Ruff, KJ [1 ]
机构
[1] Univ Tubingen, Inst Pharmaceut & Med Chem, Dept Pharm, D-72076 Tubingen, Germany
关键词
D O I
10.1021/jm0496584
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We prepared novel 1,2,4,5-tetrasubstituted imidazole derivatives with high anti-inflammatory activity by using our previously described regiospecific synthesis. Systematic optimization of the imidazole N-1 substituent resulted in compound 9b that potently inhibited the mitogen-activated protein kinase p38 (p38 IC50 = 0.218 muM) as well as the release of the proinflammatory cytokines interleukin-1beta (IL-1beta) and tumor necrosis factor alpha. (TNFalpha) from human whole blood after stimulation with LPS. Furthermore, compound 9b exhibited reduced cytochrome P450 interaction in comparison with SB203580. This result is particularly important, since cytochrome P450 interaction is observed for some p38 inhibitors and in turn can potentially cause drug-drug interaction or lead to other hepatic changes such as P450 enzyme induction.
引用
收藏
页码:6311 / 6325
页数:15
相关论文
共 42 条
[1]   Pyrimidinylimidazole inhibitors of CSBP/P37 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes [J].
Adams, JL ;
Boehm, JC ;
Kassis, S ;
Gorycki, PD ;
Webb, EF ;
Hall, R ;
Sorenson, M ;
Lee, JC ;
Ayrton, A ;
Griswold, DE ;
Gallagher, TF .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (22) :3111-3116
[2]  
ADAMS JL, 2001, SPEC PUBL R SOC CHEM, V264, P163
[3]   The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis in response to tumour necrosis factor [J].
Beyaert, R ;
Cuenda, A ;
VandenBerghe, W ;
Plaisance, S ;
Lee, JC ;
Haegeman, G ;
Cohen, P ;
Fiers, W .
EMBO JOURNAL, 1996, 15 (08) :1914-1923
[4]   1-substituted 4-aryl-5-pyridinylimidazoles: A new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency [J].
Boehm, JC ;
Smietana, JM ;
Sorenson, ME ;
Garigipati, RS ;
Gallagher, TF ;
Sheldrake, PL ;
Bradbeer, J ;
Badger, AM ;
Laydon, JT ;
Lee, JC ;
Hillegass, LM ;
Griswold, DE ;
Breton, JJ ;
ChabotFletcher, MC ;
Adams, JL .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (20) :3929-3937
[5]   New inhibitors of p38 kinase [J].
Boehm, JC ;
Adams, JL .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2000, 10 (01) :25-37
[6]   Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450 [J].
Crespi, CL ;
Miller, VP ;
Penman, BW .
ANALYTICAL BIOCHEMISTRY, 1997, 248 (01) :188-190
[7]  
DONAT C, 2000, ARCH PHARM PHARM MED, V333, P15
[8]   CHEMISTRY OF DIMETHYLKETENE DIMER .7. DIMERS OF DIMETHYLTHIOKETENE [J].
ELAM, EU ;
DAVIS, HE .
JOURNAL OF ORGANIC CHEMISTRY, 1967, 32 (05) :1562-&
[9]   Enzyme-linked immunosorbent assay for measurement of JNK, ERK, and p38 kinase activities [J].
Forrer, P ;
Tamaskovic, R ;
Jaussi, R .
BIOLOGICAL CHEMISTRY, 1998, 379 (8-9) :1101-1111
[10]  
Foster ML, 2000, DRUG NEWS PERSPECT, V13, P488